Travere reports Q3 2026 results, FILSPARI sales climb as pipeline advances
Travere posted $200.2 million in FILSPARI net product sales and said enrollment continues in its pivotal pegtibatinase trial, with a civorebrutinib IND planned by year-end.
SEC filing